Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner
JNJ and AbbVie both beat revenue expectations in Q1 2026, yet their strategies could not look more different, and which playbook actually wins depends entirely on what kind of investor you are.
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) and AbbVie (NYSE:ABBV) both posted Q1 2026 results that reshape how income investors should think about big pharma.
JNJ paired a top-line beat with a raised full-year outlook and a 64th consecutive dividend increase. AbbVie beat on revenue, missed on EPS due to a pipeline charge, and leaned harder into immunology. Same quarter, very different playbooks.
Oncology Powers One. Immunology Powers the Other.
JNJ pulled in $24.06 billion in revenue, up 9.9% YoY, with adjusted EPS of $2.70 beating the $2.6773 consensus. Oncology carried the quarter: DARZALEX hit $3.96 billion (+22.5%), CARVYKTI grew 62.1%, and TREMFYA absorbed STELARA share with 68.3% growth.
STELARA itself fell 59.7%, a roughly 920 basis point drag on Innovative Medicine. MedTech added $8.64 billion with cardiovascular up 13.0%. CEO Joaquin Duato called the portfolio and pipeline “unrivaled” after approvals for ICOTYDE and VARIPULSE Pro.
AbbVie posted $15 billion in revenue, up 12.43% YoY, with Skyrizi at $4.48 billion (+30.9%) and Rinvoq at $2.12 billion (+23.3%). Humira slid 38.6%, and adjusted EPS of $2.65 came in a hair below the $2.6676 estimate after a $744 million IPR&D charge shaved $0.41 per share. Neuroscience surprised, growing 26% on Botox Therapeutic, Ubrelvy and Qulipta.
Diversified Compounder vs. Immunology Machine
| Lens | JNJ | ABBV |
| Core Bet | Oncology + MedTech | Skyrizi and Rinvoq scaling past Humira |
| 2026 EPS Guide | $11.45 to $11.65 | $14.08 to $14.28 |
| Forward P/E | 23 | 18 |
| Dividend Yield | 2.01% | 2.65% |
| Key Vulnerability | STELARA biosimilar erosion | Humira erosion, IPR&D lumpiness |
JNJ is running a diversified compounder strategy, funding a planned Orthopaedics separation and a $1+ billion Pennsylvania cell therapy plant while raising its dividend 3.1% to $1.34. AbbVie is pouring $1.4 billion into a Durham, NC campus and pushing the non-incretin ABBV-295 obesity program toward the GLP-1 conversation.
CEO Robert A. Michael said the results were “exceeding our expectations”. Fair enough, but the IPR&D charge is a reminder that AbbVie’s earnings quality can swing more than JNJ’s.
Next Test Arrives July 15 for JNJ
JNJ reports Q2 on July 15, 2026, with Polymarket traders pricing a 92% probability of beating the $2.85 consensus. MedTech is the swing factor: traders cluster around a $9 billion revenue threshold at 71% odds.
For AbbVie, I want cleaner Skyrizi and Rinvoq numbers without another IPR&D surprise, plus early Phase 1 clarity on ABBV-295 before assuming obesity optionality is real.
Why I Split the Two by Investor Type
If I wanted a defensive core position with visible cash return, JNJ fits the profile. The $5.36 annualized dividend, low 0.235 beta, and MedTech optionality earn a steady seat in the portfolio, even after a 73.3% one-year run that has stretched the setup.
If I wanted more growth torque and a fatter yield, AbbVie is the more growth-oriented profile. Skyrizi and Rinvoq are outrunning Humira’s decay, and the 2.65% yield plus 18 forward P/E fits a growth-plus-income buyer. Investors may want to monitor both if IPR&D noise or STELARA erosion accelerates before the next earnings report.
Contact [email protected] for any questions or corrections.
Vandita Jadeja is a financial publisher with over a decade of experience writing about financial topics, including investment, savings, retirement, insurance and banking. Vandita is a Chartered Accountant who loves to debunk financial concepts for readers.
Her work has appeared on sites that include The Motley Fool, InvestorPlace, and Benzinga. She covers investing and focuses on stock picks and price prediction for 24/7 Wall St.
When not looking for the next stock investment opportunity, she can be found traveling, reading, chasing sunsets and enjoying her iced latte.
